Xenon, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Martin PhD from Bloom Burton maintained a Buy rating on the stock and has a $56.50 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Martin PhD has given his Buy rating due to a combination of factors including the promising developments in Xenon Pharmaceuticals’ early-stage pipeline. The company recently hosted an investor webinar that highlighted their focus on innovative non-opioid pain treatments targeting Kv7 and Nav1.7 channels, specifically through their XEN1120 and XEN1701 programs.
Both programs have shown significant potential, with strong efficacy and safety results in preclinical testing. Additionally, XEN1701 benefits from robust genetic validation. These advancements suggest that Xenon’s lead candidates could effectively address the limitations of previous treatments, which supports the positive outlook on the company’s stock.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $55.00 price target.